SAN DIEGO – Amongst practically 1,200 single-session facial therapies over 6 years that paired injectable hyaluronic acid filler with lasers, not one of the documented hostile occasions that occurred had been instantly associated to unfold of filler or laser therapy of the crammed space, outcomes from a single-center, retrospective research confirmed.
“Knowledge on the security of pairing single-session therapy with nonablative fractional 1,927-nm thulium and/or 1,550-nm erbium laser and fillers are missing,” Shirin Bajaj, MD, stated throughout a scientific summary session on the annual convention of the American Society for Laser Medication and Surgical procedure. “Anecdotally, we have now discovered this to be utterly secure in our high-volume laser middle. We usually do fillers first, adopted by laser therapy.”
For the research, Bajaj, a dermatology fellow on the Laser & Pores and skin Surgical procedure Middle of New York, and colleagues retrospectively reviewed the charts of 638 sufferers who had 1,186 single‐session facial therapies with nonablative fractional 1,927-nm thulium and/or 1,550-nm erbium laser (Fraxel DUAL by Solta) and injectable hyaluronic acid filler from August 2015 to June 2021. Security over the 6-year interval was assessed by the hostile occasions that occurred throughout the first 4 weeks. The imply age of sufferers on the time of therapy was 60 years and 95% had been feminine. Fitzpatrick pores and skin sorts had been sort 1 (46.1%), sort II (48.1%), sort III (5.5%), and sort IV (0.3%).
Most sufferers had 1 single‐session therapy (64.3%); the remainder had 2 classes (17.7%), 3 classes (8%), or 4-18 classes (10%). Most (91.2%) had been handled with the 1,927-nm thulium laser, whereas 1.8% had been handled with the 1,550-nm erbium laser; the imply whole vitality delivered was 1.3 kilojoules. A small variety of sufferers (7.0%) acquired therapy with each lasers.
The most typical space handled with filler injections had been the cheeks and/or tear troughs (85.6%), adopted by the perioral space and/or marionette strains (83.7%), temples (31%), nasolabial folds (25.5%), lips (24%), jawline (23.8%), chin (6.5%), brow (1.4%), glabella and brows (0.5% every), neck (0.3%), and nostril (0.1%). One syringe of filler was utilized in 58.7% of circumstances, in contrast with two syringes in 28.7% of circumstances, three syringes in 9.9% of circumstances, and 4 to 6 syringes in 2.8% of circumstances.
Bajaj reported that of the 1,186 single‐session therapies, no hostile occasions had been recorded that had been instantly associated to unfold of filler or laser therapy of the crammed space, together with product migration, sudden lack of filler quantity, vascular occlusion, acute ache, cutaneous necrosis, blindness, and cutaneous burn. There have been no hospital or emergency division transfers or admissions and referrals to ENT specialists or ophthalmologists for extra work‐up.
“That is at a busy beauty dermatology and cosmetic surgery apply,” Bajaj stated. “Extra research could also be wanted to additional validate our findings.”
The research’s lead creator was Jordan V. Wang, MD, who’s medical analysis director on the Laser & Pores and skin Surgical procedure Middle of New York.
“At most, this retrospective information confirms what we have now identified for years to be true: that mixture therapies with injectables together with fillers are secure,” Catherine M. DiGiorgio, MD, a dermatologist who practices on the Boston Middle for Facial Rejuvenation, advised this information group. “It is a small research out of a single workplace, so that may be a limitation. Nevertheless, many dermatologists have carried out Fraxel plus filler therapies in the identical session every day for the final 10 years with none points.”
DiGiorgio was requested to touch upon the outcomes and was not an investigator.
Bajaj reported having no monetary disclosures. Wang reported that he has acquired grants and/or analysis funding from ALASTIN Skincare, Cynosure, Lutronic, Novoxel, Sofwave, Solta Medical, Blossom Improvements, Allergan, Accure Pimples Inc., and Soliton. DiGiorgio reported having no related disclosures.
This text initially appeared on MDedge.com, a part of the Medscape Skilled Community.